Iopromide
(Synonyms: 碘普罗胺) 目录号 : GC32480
A contrast reagent
Cas No.:73334-07-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Iopromide is a non-ionic, water-soluble X-ray contrast agent for intravascular administration.1,2 Iopromide can cause acute kidney injury and is used in animal models of contrast-induced nephropathy.3,4
1.Ahn, Y.H., Koh, Y.I., Kim, J.H., et al.The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivityJ. Korean Med. Sci.30(3)245-251(2015) 2.Park, J.Y., Lee, S.K., Kim, J.Y., et al.A new micro-computed tomography-based high-resolution blood-brain barrier imaging technique to study ischemic strokeStroke45(8)2480-2484(2014) 3.Hassan, K., and Fadi, H.Is hypoalbuminemia a prognostic risk factor for contrast-induced nephropathy in peritoneal dialysis patients?Ther. Clin. Risk Manag.10787-795(2014) 4.Wang, N., Wei, R.b., Li, Q.p., et al.Renal Protective Effect of Probucol in Rats with Contrast-Induced Nephropathy and its Underlying MechanismMed. Sci. Monit.212886-2892(2015)
|
Animal experiment: |
Mice: Male C57/BL6J mice are randomly divided into 7 groups: control, diabetes mellitus (D), CIN, diabetes mellitus+CIN (DC), diabetes mellitus+Breviscapine (DB), CIN+Breviscapine (CIN+B) and diabetes mellitus+CIN+Breviscapine (DCB). After the model of diabetes mellitus is established, mice are prohibited drinking water for one night, and then mice are injected at a dose of 10 mL/kg iopromide via tail vein administration over the course of 1 minute. Then the mice are treated intragastrically with or without Breviscapine (10 mg/kg/d) for 4 weeks. Other mice groups except for Breviscapine treatment groups (DB, DCB and CIN+B) are administered the same volume of phosphate buffered solution intragastrically for 4 weeks. Then mice are sacrificed by an intraperitoneal injection of chloral hydrate[1]. |
|
References: [1]. Jiang W, et al. Breviscapine attenuatted contrast medium-induced nephropathy via PKC/Akt/MAPK signalling in diabetic mice. Am J Transl Res. 2016 Feb 15;8(2):329-41. |
|
| Cas No. | 73334-07-3 | SDF | |
| 别名 | 碘普罗胺 | ||
| Canonical SMILES | O=C(C1=C(I)C(NC(COC)=O)=C(I)C(C(NCC(O)CO)=O)=C1I)N(CC(O)CO)C | ||
| 分子式 | C18H24I3N3O8 | 分子量 | 791.11 |
| 溶解度 | DMSO : ≥ 150 mg/mL (189.61 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.264 mL | 6.3202 mL | 12.6405 mL |
| 5 mM | 0.2528 mL | 1.264 mL | 2.5281 mL |
| 10 mM | 0.1264 mL | 0.632 mL | 1.264 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet